Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GLUE vs AURA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AURA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 3–7 Matrix Metrics)

AURA Overall Winner 6-Pillar Tally: GLUE 2 – 3 AURA (1 Tie) Matrix Metrics: GLUE 7 – 3 AURA

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.11 (10.0x Forward P/E, -214.5% operating margin), whereas AURA carries 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While GLUE currently prints a higher short-term Unified Composite Score (44.2/100 HOLD vs. AURA 28.8/100 SELL), AURA captures the overall institutional head-to-head verdict (3–7 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -214.5% operating margin) and revenue trajectory (+0.0% vs. +325.8% YoY).
  • Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GLUE vs AURA
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.11
-2.77% 1D
Market Cap $795.5M
TTM Revenue $70M
Forward P/E 10.0x
Beta / 30D Vol 0.94β · 53% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.2%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $10.50 · SMA50: $11.21
AURA NASDAQ Head-to-Head Winner
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 50.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 58.7 · SMA20: $6.66 · SMA50: $6.54

6-Pillar Scorecard Institutional Category Breakdown (GLUE 2 – 3 AURA)

Columns: Metric · GLUE · AURA
1. Valuation Multiples GLUE
Forward P/E 10.0x N/M
Trailing P/E 10.0x N/M
PEG Ratio N/M N/M
EV / Revenue 11.2x N/M
2. Growth & Scale GLUE
Revenue Growth (YoY) +325.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $70M N/A
Market Cap $795.5M $728.6M
3. Profitability & Quality AURA
Gross Margin -92.2% N/A
Operating Margin -214.5% 0.0%
Net Profit Margin -186.2% 0.0%
Return on Equity (ROE) -35.3% -61.7%
4. Balance Sheet & Cash Flow AURA
Cash Generation (TTM) -$174M -$110M
Cash Flow Margin N/A N/A
Net Cash / Leverage $8.9M Net Cash $26M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AURA
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 100.8% (16th %ile) 160.1% (22nd %ile)
Put/Call OI Skew 6.27x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GLUE (7) vs AURA (3)
Institutional Metric GLUE AURA Criterion Row Edge
Market Capitalization
Scale
$795.5M $728.6M Larger Scale GLUE
Trailing P/E Ratio
Valuation
10.0x N/M Lower Multiple GLUE
Forward P/E Ratio
Valuation
10.0x N/M Lower Multiple GLUE
Revenue Growth (YoY)
Growth
+325.8% +0.0% Higher Growth GLUE
Operating Margin (TTM)
Profitability
-214.5% 0.0% Higher Margin AURA
Net Profit Margin
Profitability
-186.2% 0.0% Higher Margin AURA
Return on Equity (ROE)
Capital Efficiency
-35.3% -61.7% Higher ROE GLUE
52-Week Range Position
Momentum
1% ($9–$26) 52% ($5–$10) Stronger Trend AURA
Beta / 30D Volatility
Risk Regime
0.94β · 53% Vol 0.92β · 75% Vol Lower Realized Risk GLUE
Unified Institutional Score
Composite Signal
44.2 / 100 (HOLD) 28.8 / 100 (SELL) Higher Composite GLUE
Trailing 12M Revenue (USD)
Operating Scale
$70M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-92.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 11.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$174M ($8.9M Net Cash) -$110M ($26M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AURA +24.67 pp
GLUE: -6.47% · AURA: +18.2%
3M Horizon AURA +27.75 pp
GLUE: -39.39% · AURA: -11.64%
6M Horizon AURA +45.94 pp
GLUE: -49.42% · AURA: -3.48%
1Y Horizon AURA +66.76 pp
GLUE: -36.38% · AURA: +30.38%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GLUE vs AURA. Trailing 12-month operating profitability (GLUE -214.5% vs AURA 0.0%) and valuation multiples (GLUE 10.0x vs AURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GLUE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$70M
Gross Margin-92.2%
Op. Margin-214.5%
ROE / Fwd P/E-35.3% · 10.0x
AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GLUE BREAKDOWN
85d in phase · OBV DISTRIBUTION
Current IV 100.8%
IV Percentile 16th %ile
Put/Call OI Skew 6.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GLUE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GLUE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $795.5M market capitalization and -214.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GLUE vs AURA Key Questions & Quantitative Answers

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) is the stronger overall head-to-head candidate over Monte Rosa Therapeutics, Inc. (GLUE) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.11 (10.0x Forward P/E, -214.5% operating margin), whereas AURA carries 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While GLUE currently prints a higher short-term Unified Composite Score (44.2/100 HOLD vs. AURA 28.8/100 SELL), AURA captures the overall institutional head-to-head verdict (3–7 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -214.5% operating margin) and revenue trajectory (+0.0% vs. +325.8% YoY). Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GLUE leads the Growth & Scale pillar: GLUE posts +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (-92.2% gross margin, -214.5% operating margin), compared with AURA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, GLUE generates $70M in USD-normalized revenue versus N/A for AURA. In operating R&D and SG&A reinvestment, GLUE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AURA.

GLUE screens cheaper on headline valuation multiples. GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (unreported FCF margin), whereas AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GLUE (-35.3% ROE) versus AURA (-61.7% ROE) capital efficiency.

In options market volatility and institutional positioning, GLUE carries 100.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 6.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.94β · 53% Vol realized risk). By comparison, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.